Takeda Pharmaceutical Company Limited (TKPHF)
OTCMKTS
· Delayed Price · Currency is USD
26.30
0.00 (0.00%)
May 22, 2025, 4:00 PM EDT
TKPHF Revenue
In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T JPY with 7.45% growth. Takeda Pharmaceutical Company had revenue of 1.05T in the quarter ending March 31, 2025, with 0.24% growth.
Revenue
4,581.55B JPY
Revenue Growth
+7.45%
P/S Ratio
1.47
Revenue / Employee
92.97M JPY
Employees
49,281
Market Cap
45.06B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 4,581.55B | 317.79B | 7.45% |
Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
American Oncology Network | 1.76B |
Takeda Pharmaceutical Company News
- 8 days ago - The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 - Business Wire
- 12 days ago - Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise - Seeking Alpha
- 13 days ago - Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO - CNBC
- 14 days ago - Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs - Benzinga
- 14 days ago - Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs - Benzinga
- 15 days ago - Earnings Scheduled For May 8, 2025 - Benzinga
- 15 days ago - Takeda Pharmaceutical Non-GAAP EPS of ¥491.00, revenue of ¥4581.6B; initiates FY25 outlook - Seeking Alpha